biotechnology-enzymology-2019-scientifictracks

8 / 12

Page 40
Notes:
conferenceseries.com
Volume 9 Journal of Biotechnology & Biomaterials
ISSN: 2155-952X
JOINT EVENT
February 28-March 02, 2019 | Berlin, Germany
5th International Conference on
Enzymology and Protein Chemistry
&
22nd Global Congress on Biotechnology
Biotechnology 2019
Enzymology 2019
February 28-March 02, 2019
&
Aldehyde dehydrogenases as target for biomarker and drug discovery
Klaus Pors
University of Bradford, UK
The human aldehyde dehydrogenases (ALDHs) play a major role in detoxifying highly reactive aldehydes into carboxylic
acids. Deregulation of ALDHs have implications in a number of cancers. They play an important role as a cancer stem cell
(CSC) marker due to high activity found in CSCs while high expression is also known to lead to resistance to chemotherapeutic
drugs. Although the exact role of ALDH is not fully understood, emerging information indicates several isoforms from the
ALDH1 family, ALDH3A1 and ALDH7A1 play key roles in many cancer types. To probe the role of ALDH functional activity,
at this meeting we will present new data on small molecules that inhibits ALDH functional activity using cell free and cell-
based assays; diethylbenzaldehyde (DEAB) was used as a control for inhibition while Aldefluor assay was used as an assay to
demonstrate functional activity. Furthermore, our investigations in prostate cancer revealed that several ALDH-affinic probe
compounds were able to reduce cell viability in both drug-resistant PC3 prostate cancer cells and patient-derived samples while
synergistic effect was observed in combination treatment with docetaxel. Our early drug discovery approach will be presented
at the meeting and include drug design to target ALDH7A1, an enzyme that is linked with oxidative stress, lysine metabolism
and several diseases including cancer.
Biography
Klaus Pors is anAssociate Professor of Chemical Biology at The Institute of Cancer Therapeutics, University of Bradford, UK. His research group is involved with discovery
of novel biological and chemical tools to explore the importance of enzymes in different disease states. Particular focus is on exploiting abnormal cytochrome P450
(CYP), aldehyde dehydrogenase (ALDH) or aldo-keto reductase (AKR) expression in the tumour microenvironment as target for biomarker and drug discovery; he has
published 35 papers on these topics. He is a RSC Chemical Biology and Bioorganic Group committee member and the European Editor of Journal of Cancer Metastasis
and Treatment.
Klaus Pors, J Biotechnol Biomater 2019, Volume 9
DOI: 10.4172/2155-952X-C2-115